Squamous cell cancer of the esophagus: The forgotten one

Gastrointestinal Cancer Research

Volumn 4, Issue 1, 2011, Pages 22-23

  Leichman, Lawrence ^a   Thomas Jr , Charles R ^a  

^a Desert Comprehensive Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLIN D1; CYCLIN E; DOCETAXEL; PLATINUM DERIVATIVE; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; TAXANE DERIVATIVE;

ALCOHOL CONSUMPTION; CANCER INCIDENCE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; DISTANT METASTASIS; DRUG RESPONSE; DYSPHAGIA; EDITORIAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; HUMAN; OCCULT CANCER; ODYNOPHAGIA; OVERALL SURVIVAL; RACE DIFFERENCE; RISK FACTOR; SMOKING; TRACHEOESOPHAGEAL FISTULA; WEIGHT REDUCTION;

EID: 79955582403     PISSN: 19347820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (17)

1. Brown LM, Devesa SS, Chow WH: Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 100:1184-1187, 2008
2. Ferlay J, Bray F, Pisani P, et al: GLOBOCAN 20002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Bse No 5 [version 2.0] Lyon, France IARC.
3. Surveillance, Epidemiology and End Results (SEER) Program (www.seer.cancer.gov) SEER * Stat database: Incidence-SEER 9 Regs Limited-USE, Nov 2006 Sub (1973-2004)-Linked to County Attributes-Total US, 1969-2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
4. Brown LM, Devesa SS: Epidemiology and Risk of Esophageal Cancer: Clinical. In: Jobe BA, Thomas CR, Hunter JG eds. Esophageal Cancer: Principles and Practice. Demos Medical Publishing, LLC New NY.
5. Gibbons MA, Brock M, Alberg AJ, et al: The sociobiologic integrative model (SBIM): enhancing the integration of sociobehavorial, environmental, and biomolecular knowledge in urban health and disparities research. J Urban Health 84:198-211, 2007
6. Guo M, Ren J, Brock M, et al: Promoter methylation of HIN-1 in the progression to esophageal squamous cancer. Epigenetics 3:336-341, 2008
7. Souza RF: Molecular and biologic basis of upper gastrointestinal malignancy-esophageal cancer carcinoma. Surg Oncol Clin N Am 11: 257-272, 2002
8. Van Cutsem E, Kang Y, Chung H, et al: Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC), J Clin Oncol 27:, 2009 (abstr LBA4509)
9. Jemal A, Murray T, Samuels A, et al: Cancer statistics 2003. CA Cancer J Clin 53:5, 2003
10. Stahl M, Stuschke M, Lehmann N, et al: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23: 2310-2317, 2005
11. Bedenne L, Michel P, Bouche O, et al: Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FCD 9102). Proc Am Soc Clin Oncol 21:, (abstr 519), 2002
12. Gaast AV, van Hagen P, Hulshof M, et al: Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized trial. J Clin Oncol 28:, 2010 (abstr 4004)
13. Rossman JF, Falkson CI, Xu R, et al: Phase II trial of docetaxel and carboplatin in patients with advanced squamous carcinoma of the esophagus (E2298): a trial of the Eastern Cooperative Oncology Group. Gastrointest Cancer Res 4:9-14, 2011
14. Hers B, Dalichau H, Wormann B, et al: Induction combination chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer. Thorac Cardiovasc Surg 46: 298-302, 1998
15. Ilson D, Ajani J, Bhalla K: Phase II trial of paclitaxel, fluorouracil and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16:1826-1834, 1998
16. Penel N, Adenis A: Publication biases and phase II trials investigating anticancer targeted therapies. Invest New Drugs 27:287-288, 2008
17. Institute of Medicine of the National Academies: A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. April 2010. (Available online at http://www.nap.edu/catalog.php?record_ id_12879#toc)